Vistin Pharma Asa · OSL:VISTN

Vistin Pharma Asa — Redeye Theme Event Diabetes 2026

19 slides from Vistin Pharma Asa's conference presentation, May 6, 2026

  1. Slide 1: Redeye Theme Event Diabetes

    Redeye Theme Event Diabetes Stockholm - 6 May 2026 Magnus Tolleshaug – CEO

  2. Slide 2: Norwegian pharmaceutical company producing Metformin Hydrochloride

    Norwegian pharmaceutical company producing Metformin Hydrochloride.

  3. Slide 3: Introduction Vistin Pharma

    Introduction Vistin Pharma – Long and successful track record of producing high quality API  Vistin is a dedicated metformin pharmaceutical company with a current installed production capacity of Revenues Vistin Metformin (MNOK) 500 >6 000 metric tons 452 450 439 430  Metformin API (Active Pharmac

  4. Slide 4: Vistin Pharma locations

    Vistin Pharma locations Manufacturing Plant Oslo headquarter Site Fikkjebakke, Kragerø Østensjøveien, Oslo • ~75 employees • 6 employees • Opened 2002 • Administration • Manufacturing of Metformin • Finance HCl and DC • Regulatory Affairs • QC laboratory and release center (QA) • Sales • Procurement

  5. Slide 5: Slide 5

  6. Slide 6: 590 million adults living with diabetes, expected to increase 45% by 2050

    590 million adults in the world today is living with diabetes, this is expected to increase by 45% within 2050 Number of people living with diabetes / Source International Diabetes Federation, IDF Diabetes Atlas, eleventh edition, 2025

  7. Slide 7: Global Metformin API demand expected to grow to 104,000MT by 2030

    Global Metformin API demand expected to grow by approximately 28.000MT to 104.000MT by 2030 GLOBAL SALES DEVELOPMENT BY PRODUCT (METRIC TONS) 2019 - 2030 QTR RESEARCH 2024 120000 100000 80000 60000 40000 20000 0 2019 2020 2021 2022 2023 2024E 2025F 2026F 2027F 2028F 2029F 2030F Metformin DC Metformi

  8. Slide 8: Vistin Pharma world wide sales footprint – 100% export out of Norway

    Vistin Pharma - world wide sales footprint – 100% export out of Norway

  9. Slide 9: Slide 9

  10. Slide 10: Average annual revenue growth ~10%, EBITDA growth ~27%

    Average annual revenue Average annual EBITDA growth ~10% growth ~27% Revenue MNOK EBITDA MNOK 500 140 452 450 438 430 120 115 400 104 350 100 305 86 300 279 80 250 60 200 44 150 40 100 20 50 6 0 0 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 2025: Preliminary results 2022 EBITDA affected by ins

  11. Slide 11: Committed to predictable annual returns to the shareholders

    Committed to predictable annual returns to the shareholders Earnings per share increased by ~200% from 2021-2025 1,80 1,69  Dividend 2023. NOK 0.75 (paid out in 2024) 1,60 1,42 1,40 1,20  Dividend 2024: NOK 1 per share 1,03 1,00 0,80  Dividend 2025: NOK 1.25 per share 0,56 0,60 0,40  Proposed di

  12. Slide 12: Strong balance sheet

    Strong balance sheet Assets 31.12.2025 31.12.2024 Total non-current assets 235 909 241 757  Non-current assets mainly buildings and machines Total current assets 203 524 143 187 related to manufacturing site Total Assets 439 432 384 945  Strong balance sheet with an equity ratio of 75% Equity and

  13. Slide 13: Slide 13

  14. Slide 14: Vistin Pharma – Uniquely positioned

    Vistin Pharma – Uniquely positioned – A leading global supplier of Metformin Independent and dedicated Premium Quality Integrity in a Metformin producer competitive market • Provide high flexibility and exeptional • High quality Metformin API reduce brand delivery performance to customers and patien

  15. Slide 15: Strategic intent: optimize and grow current business

    Strategic intent: Optimize and grow our current business, strengthen our premium metformin supplier position…  Build a >7000 metformin business through world class operations and strategic customer partnerships  Make our manufacturing plant in Norway the most technology advanced and environmentall

  16. Slide 16: Slide 16

  17. Slide 17: Vistin Pharma

    — Vistin Pharma

  18. Slide 18: Metformin is used in 1st-line treatment for T2D

    Metformin is used in 1st-line treatment for T2D Metformin used to lower glucose Metformin combined with other (blood sugar) levels APIs are second- and third-line treatments, often high-priced • Reduces the liver’s production of patent-protected fixed dose glucose Medical rationale combination produ

  19. Slide 19: Number of people living with diabetes

    Number of people living with diabetes / Source International Diabetes Federation, IDF Diabetes Atlas, eleventh edition, 2025

Vistin Pharma — Redeye Theme Event Diabetes 2026 on 6ix